Key result
Dox-DSPIONs demonstrated sustained-release properties, prolonged blood circulation time, and reduced distribution in the heart and kidney compared to free doxorubicin in mice.
Why the study?
Clinical application of doxorubicin is strictly limited by a short biological half-life and serious side effects, particularly for the heart and kidney.
Does Dox-DSPIONs alter the pharmacokinetics and biodistribution compared to free doxorubicin in preclinical models?
Does Dox-DSPIONs alter the pharmacokinetics and biodistribution compared to free doxorubicin in preclinical models?
Dox-DSPIONs provide sustained release and reduce cardiac distribution of doxorubicin in preclinical models, potentially mitigating cardiotoxicity.
BACKGROUND: Due to the short biological half-life and serious side effects (especially for heart and kidney), the application of Doxorubicin (Dox) in clinical therapy is strictly limited. To overcome these shortcomings, a novel sustained release formulation of doxorubicin-loaded dextran-coated superparamagnetic iron oxide nanoparticles (Dox-DSPIONs) was prepared. OBJECTIVE: The purpose of this study was to evaluate the intracellular uptake behavior of Dox-DSPIONs and to investigate their pharmacokinetics and biodistribution properties. METHOD: Confocal laser scanning microscopy was employed to study the intracellular uptake and release properties of Dox from Dox-DSPIONs in SMMC-7721 cells. Simple high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method was established to study the pharmacokinetics and biodistribution properties of Dox-DSPIONs in vivo after intravenous administration and compared with free Dox. RESULTS: of Dox-DSPIONs was significantly lower than that of free drug. The biodistribution behaviors of the drug were altered by Dox-DSPIONs in mice, which showed obvious liver targeting, and significantly reduced the distribution of the drug in the heart and kidney. CONCLUSION: Dox-DSPIONs have the sustained-release property in vitro and in vivo, which could significantly prolong blood circulation time, improve bioavailability, and reduce the side effects of Dox. Therefore, the novel formulation of the Dox-DSPIONs has the potential as a promising drug delivery system in cancer therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Cancer. Doxorubicin-loaded dextran-coated superparamagnetic iron oxide nanoparticles (Dox-DSPIONs) vs. Free Doxorubicin was evaluated on Intracellular uptake, pharmacokinetics, and biodistribution. Dox-DSPIONs demonstrated sustained-release properties, prolonged blood circulation time, and reduced distribution in the heart and kidney compared to free doxorubicin in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: